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CHAPTER -1 
 
INTRODUCTION 
 
Chemistry is a very broad subject, and can justly claim to encompass many aspects 
of the study of biological molecules. To most researchers in the cancer fields, the term 
 
„chemistry‟ is often used in a much narrower way and is synonymous with the synthetic 
chemistry as a tool for the discovery of anticancer drugs. 
 
1.1. PHARMACEUTICAL CHEMISTRY 
 
Pharmaceutical Chemistry is an area of chemistry that deals with the structure, 
properties and reaction of compounds that contains carbon. Chemists in general and 
organic chemists in particular can create new molecules never before proposed which, if 
carefully designed, may have important properties for the betterment of the human 
experience. One of the main objectives of organic and medicinal chemistry is the design, 
synthesis and production of molecule having value as human therapeutic agents
1
.The 
department of pharmaceutical chemistry is to impart in depth knowledge about all the 
chemical aspects of drugs and natural products, such as the structure, synthesis, isolation 
and structural activity relationship with the pharmacological activity. 
 
Medicinal chemistry 
 
Medicinal chemistry and bioorganic chemistry is concerned with the design, 
synthesis and analysis of the relationship between molecular structure and biological 
activity for compounds that can be used for the care or treatment of disease
1
.In medicinal 
chemistry, the chemist attempts to design and synthesis a medicine or pharmaceutical 
agent which will benefit humanity. Such a compound could be called as drug.Medicinal 
chemistry is a part of pharmaceutical chemistry. Medicinal chemistry is discipline at the 
intersection of chemistry and pharmacology involved with designing, synthesizing and 
developing pharmaceutical drugs. Medicinal chemistry involves 
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theidentification, synthesis and development of new chemical entities suitable for 
therapeutic use. It also includes the study of existing drugs, their biological properties and 
their quantitative structure activity relationship (QSAR). 
 
Medicinal chemistry is the application of chemical research techniques to the 
synthesis of pharmaceuticals. During the early stages of medicinal chemistry development, 
scientist were primarily concern with the isolation of the medicinal agents founds in 
plants. Today, scientists in this field are also equally concerned with creation of new 
synthetic drug compounds. Medicinal chemistry almost always geared towards drug 
discovery and development. 
 
The first step is pharmaceutical focused on quality aspects of medicines and aims 
to assure fitness for the purpose of medicinal products. Medicinal chemistry is a highly 
interdisciplinary science combining organic chemistry with biochemistry, computational 
chemistry, pharmacology, pharmacognosy, molecular biology, statistics and physical 
chemistry.The second step of drug discovery involves the synthetic modification of the 
hits in order to improve the biological properties of the compound pharmacophore. 
 
Heterocyclic Chemistry is the chemistry branch dealing exclusively with 
synthesis, properties and application of heterocyclic. Heterocyclic compound is an organic 
compound that contains a ring structure containing atom in addition to carbon, such as 
sulfur, oxygen or nitrogen as part of the ring. They may be either simple aromatic or non-
aromatic rings. Some heterocyclic compounds are known as carcinogens. Researchers have 
shownthat heterocyclic amines are the carcinogenic chemicals. 
A heterocyclic compound is one which possesses a cyclic structure with at least two 
different kinds of hetero atoms in the ring. Nitrogen, oxygen and sulfur are most common 
hetero atoms. Heterocyclic compounds are very widely distributed in nature and are 
essential to life in various ways. 
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1.2. THIAZOLIDINEDIONE 
 
Thiazolidinedione‟s (often referred to colloquially as „glitazones‟) are oral 
antidiabetic agents widely used to treat patients with T2DM that act primarily as insulin 
sensitizers, improving glucose control and decreasing insulin resistance. Rosiglitazone and 
pioglitazone are two compounds in this class of insulin sensitizing drugs presently 
approved for use in many countries as immunotherapy or in combination with metformin, 
sulfonylureas or insulin. It is well established that they enhance peripheral glucose uptake 
and improve insulin sensitivity in patients with Type2 DM
1
 and prevent progression to 
Type 2 DM in patients with impaired glucose tolerance and insulin resistance
2
. 
 
Thiazolidinedione‟shad a major effect on adipose tissue and skeletal muscle and are also 
active in liver
3
. They are more effective in increasing insulin sensitivity than the biguanide 
metformin, which acts primarily on the liver and to a lesser extent on the skeletal muscle by 
a still unknown mechanism
4
. 
 
Thiazolidinedione‟s exhibit a number of potential anti-atherogenic actions in type 2 
diabetic patients, including: improvement in lipoprotein profiles via the reduction of 
oxidized LDL
5
, circulating triglyceride levels
6,7
, improvements in vascular reactivity via 
suppression of endothelin-1 levels and inhibition of extracellular calcium uptake by 
vascular smooth muscle cells (VSMC), apparently through inhibition of L-type calcium 
channels
8
. TZD also inhibit vascular smooth muscle cell proliferation and migration
9
. They 
have also been shown to improve endothelial function, reduce inflammation and decrease 
plasma FFA and blood pressure
10
.Further details regarding the history of this class of 
medication, their chemical structure and their relationship to other anti-diabetic agents can 
be found in recent reviews by YkiJarvinen and Natali and Ferrannini. 
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1.1. Modes of Action of Thiazolidinediones 
 
Thiazolidinedione‟s act on adipose tissue to decrease plasma free fatty acids (FFAs) 
and secretion of tumor necrosis factor-α (TNF- α) and resist in, often increased with obesity 
and diabetes, therefore improving insulin action in muscle, adipose tissue and liver. They 
are believed to increase insulin sensitivity by activating highly selective and potent nuclear 
receptors, the peroxisome proliferator-activated receptor-gamma (PPARγ), thereby directly 
regulating gene expression as a result of which peripheral glucose uptake is increased and 
hepatic glucose production is diminished
11-13
. The PPARs are a family of nuclear receptors 
comprised of three different subtypes, α, β and γ. PPARs receptors are found in target 
tissues for insulin action such as skeletal muscle, adipose tissue, and liver and it appears 
that they are important regulators for insulin action, lipid homeostasis and adipocyte 
differentiation. Once activated, the receptors alter transcription of numerous target genes by 
interacting with specific DNA response elements located upstream of responsive genes (Fig 
1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.Activation of the PPAR receptors leading to the transcription of the responsive gene.
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Legend:  
PPAR= peroxisome proliferator-activated receptor, RA= retinoic acid, PPRE= 
peroxisome proliferators response element, RXR retenoid X receptorPPARγ regulation of 
gene expression occurs primarily in adipose tissue where, among other things, under 
anaerobic conditions it promotes lipogenesis
14
. The effects of PPARγ activation on 
glucose, lipid and insulin metabolism provide therapeutic potential for exogenous ligands of 
this receptor to reduce altered glucose and insulin metabolism and redress the metabolic 
abnormalities of T2DM
15
. Further discussion regarding differential action of TZDs on 
PPAR can be found in Yki-Jarvinen‟s review paper
13
. 
 
Other properties of thiazolidinediones that may contribute to their blood pressure 
lowering actions include inhibitory effects on vascular smooth muscle cell (VSMC) 
migration and proliferation, mentioned above. In this manner, thiazolidinediones appear to 
inhibit a key step in the development of atherosclerotic plaque, which typically involves 
VSMC migration from media to intima, proliferation of VSMCs and subsequent increased 
production of extracellular matrix proteins
16
. VSMC migration and proliferation are 
thought to represent essential processes in the development of vascular remodeling, 
atherosclerosis and diabetic organ complications (Fig 2). It is noted that the evidence for 
apparently beneficial effects of TZD on these processes derives from in vitro and animal 
studies and that their clinical implications for humans remain to be fully elucidated. 
 
1.3. CANCER AND ANTI CANCERAGENTS 
 
 
Today, the Greek term carcinoma is the medical term for a malignant tumor derived 
from epithelial cells. It is cells who translated carcinomas in to the latin cancer, also 
meaning crab. Galen used “oncos” to describe all tumors, the root for the modern word 
 
oncology
17-30
. 
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Cancer is an important public health on concern and in developed countries it represents 
the second leading cause of death, after cardiovascular disease. The resistance to chemo 
therapeutic anti-tumoragents by cancer cells could be minimized using a combination of drugs 
with different and complementary mechanism of action. Therefore, there is a need to discover 
and develop useful new lead compounds of simple structure, exhibiting optimal in-vivo anti-
tumor potency and new mechanism of action. 
 
Cancer is a disease in which a group of cells divides abnormally without any 
control,even destroy other tissues. These cells spread all over the body through the blood and 
lymph, giving rise to satellite lesions elsewhereand then eventually leading to death. 
 
Cancer is one of the most wide spread and feared diseases in the western world today 
feared largely because it is known to be difficult to cure. The main reason for this difficulty is 
that cancer results from the uncontrolled multiplication of subtly modified normal human 
cells.One of the main method so far modern cancer treatments is drug therapy (chemotherapy). 
Cancer is a major disease about one in four people will getting some form during their lifetime, 
and at the present time about one in five of all death are due to cancer.Currently the rare three 
major ways of treating cancer: 
 
 Radiation therapy 


 Surgery 


 Cytotoxic drugs. 
 
 
Cancer arises from the mutation of a normal gene. Mutated genes that cause cancer are 
called oncogenes. A factor which brings about a mutation is called a mutagen. Any agent that 
causes a cancer is called a carcinogen and is described as carcinogenic. 
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Fig.No.1 Types of cancer scell division 
 
 
Types of tumor 
 
1. Benign tumors (do not spread from their site of origin, but can crowd out (squash) 
surrounding cells e.g. brain tumor 
2. Malignant tumours (can spread from the original site and causes secondary tumours. This is 
called metastasis. They interfere with neighboring cells and can block blood vessels, the gut, 
glands, lungs etc.) 
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The Cell Cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.No.2 Phases of Cell cycle 
 
 
 The cell cycle consists of four stages G1, S, G2 and M. 

 G1 and G2 are 'gap' phases in which the cell grows and prepares to divide. 

 S is the synthesis phase in which the chromosomes (DNA) are copied (replicated). 

 M is the mitotic phase in which the cell physically divides in to two daughter cells. 

 Most cells are NOT actively dividing. These cells are in a resting state(G). 
 
Mitosis (M phase) 
 
 Mitosis in normal cells produces two cells with identical genetic 
content. Mitosis has four sub-phases. 

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 Prophase - Chromosomes condense, then unclear membrane breaks down and spindle fibres 
form. 

 Metaphase – The replicated chromosomes line up in the middle of the cell. 
 Anaphase – Chromosomes separate and thecell becomes elongated with distinct ends 
(poles). 


 Telophase - Nuclear envelopes reform at the two poles and new cell membranes are formed 
to create two independent cells. 

 Cytotoxicity is the cell killing property of a chemical compounds. Cell death can occur by 
 
either of two distant mechanisms, necrosis or apoptosis.Necrosis is physical or chemical 
damage,  where  apoptosis  is  the  physiological  process  by  which unwanted cells  are 
eliminated during development and other normal biological processes.   
Types of cancer  
   
Lung Cancer  Lung 
   
Breast Cancer  Breast 
   
Cervical Cancer  Cervical 
   
Colon Cancer  Colon 
   
Leukemia  Blood 
   
Testicular Cancer  Testis 
   
Brain Cancer  Brain 
   
Kidney Cancer  Kidney 
   
Thyroid Cancer  Thyroid Gland 
   
Liver Cancer  Liver 
   
Bone Cancer  Bone marrow 
   
TableNo.1 Types of Cancer  
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Causes of cancer 
 
 DNA Mutation 

1. Radiation – other environmental (tobacco, alcohol, radon,asbestos, chemicals etc).  
 
2. Random somatic mutations  
 
3. Inherited germ line mutations  
 
 Genetic predisposition – 

2. Rb, p53, APC, CDKN2A, BRCA1, BRACA  
 
 Infectious agents 

1. Viral  
 
 
A. HPV (Human papilloma virus) – cervical cancer  
 
 
B. Hepatitis – liver cancer  
 
 
2.  Bacterial 
 
 
A. H. pylori– stomach cancer 
 
 
Diagnosis of cancer 
 
 Biopsy of the tumor 
 Blood tests (which look for chemicals such as tumor makers) 
 Bone marrow biopsy (for lymphoma or leukemia) 
 Chest x-ray 
 Complete blood count 
 

 CT scan &   MRI scan 
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Treatment of Cancer Traditional treatment 
 
 
1. Surgery: it is the first treatment which is used to removed solid tumors, and for 
early stage cancer and benign tumors.  
 
2. Radiation: it kills the cancer cells with high energy ray stargeted to the tumor. It 
acts by damaging DNA and preventing its replication.  
 
Newer treatment 
 
 
1. Hormone therapy:  by using Hormones and anti – Hormone.  
 
 
2. Chemotherapy: Chemotherapy means treatment with anticancer drugs and they 
are given to destroy or control cancer cells.  
 
1.4 CERVICAL CANCER  
 
 
The American Cancer Society‟s most recent estimates for cervical cancer in the 
 
United States are for 2011: 
 
 
 About 12,710 new cases of invasive cervical cancer will be diagnosed per year. 

 About 4,290 women will die from cervical cancer per year 
 
 
 
Cervical cancer is one of the most common types of cancer and a majority mortality 
factor of women worldwide.The cervix is the lower part of the uterus (womb). The part of the 
cervix closest to the body the uterus is called the endocervix. The part next to the vagina is the 
exocervix. The two main types of cells covering the cervix are squamous cells (on the 
endocervix). The place where these two cell types meet is called the transformation zone. Most 
cervical cancers start in the transformation zone. 
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Normally, cervical cells grow in an orderly fashion. However, when controls of that 
grow this lost, cells divide too frequently and too fast. Nearly all cervical cancers arise of the 
inner of the cervix. 
 
There are several types of cervical cancer: 
 
 
Squamous cell carcinoma (SCC) is the most common type of cervical cancer, 
accounting for 85% to 90% of all cases. It develops from the cells that line the inner part of the 
cervix, called the squamous cells. 
 
Adenocarcinoma develops from the column shaped cells that line the mucous 
producing glands of the cervix. In rare instances, adenocarcinoma accounts for about 10% of all 
cervical cancers. 
 
Mixed  carcinomas  (adenosquamouscarcinomas)  combine  features  of  both 
 
squamous cell carcinoma and adenocarcinoma. 
 
 
Treatment of Cervical Cancer 
 
 
 Surgery 

 Pre invasive cervical cancer 

 Cryosurgery 

 Laser surgery 

 Invasive cervical cancer 
 
 
Simple hysterectomy– removal of the body of the uterus and cervix 2. Radical 
hysterectomy and pelvic lymph node dissection removal of entire uterus, surrounding tissue, 
upper part of the vagina and lymph nodes from the cervix. 
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 Radiation 
 Chemotherapy 
 
 
The drugs used to combat cancer belong to one of the two broad categories. The first is 
cytotoxic drugs (cell killing) and the second is cytostatic drugs (cell stabilizing). Both the 
categories lead to are duction in the size of tumor because cancer cells (for various reasons) 
have such a high mortality rate that simply preventing them from dividing will lead to are 
duction in the population. 
 
The majority of drugs used for treatment of cancer today are cytotoxic (cell killing) 
drugs that work by interfering in someway with the operation of the cell‟s DNA. Cytotoxic 
drugs have the potential to be very harmful to the body unless they are very specific to cancer 
cells something difficult to achieve because the modifications that change a healthy cell in to a 
cancerous one are very subtle. A major challenge is to design new drugs that will be more 
selective for cancer cells, and thus have lesser side effects.The development of a new 
pharmaceutical is a complex process, but can be broken down to three main steps: 
 
 Discovery of a new potentially use full molecule. 

 Appropriate molecular modification to produce a molecule with the best combination of 
properties. 

 Development of this molecule in to a safe and affordable drug. 
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Fig.No.4 MOA of Cytotoxic drugs 
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2. REVIEW OF LITERATURE  
Various thiazolidinedione derivatives have been developed by structural modifications in 
order to enhance the biological property such as anthelmintic activity. Herein a detailed literature 
survey is described for thiazolidinedione. 
1.Shashikanth PR and coworkers
31
 have reported synthesis of  thiazolidinedioneanalgous using 
microwave irradiation and screened for anti diabetic activity on albino rats. They were found to 
have good anti diabetic activity when compared with standard drug glibenclamide.  
2.Metelko Z and others
32
 developed combination of glitazars with PPARγ and PPARα 
agonist.They found that the combination may potentially improve insulin resistance and alleviate 
atherogenic dyslipidemia.
 
3.Evranos B et al
33
has reported the synthesis and evaluation of thiazolidinedionesanalougs for 
aldose reductase activity. Thiazolidinedione analogous are also reported to have 
aldolasereductase inhibits activities , when they substituted with cromonyl moiety.
 
New oxime containing thiazolidinedione are reported useful for hyperglycemia, hyperlipidemia 
and gestational diabetes mellitus as reported by Imran and coworkers
34
. 
4.Lucia Frenanda C and coworkers
35
 have reported new arylidene-thiazolidinediones (ATZDs) 
were synthesized and evaluated in the alloxan-induced hyperglycemia mice model. The 
molecular target taken into consideration is the nuclear PPAR-γ whose crystallographic structure 
is available on the PDB database as 2PRG.  
5.Chandra R and coworkers
36
 have synthesized thiazolidinedione derivative and are found to 
have good hypolipidemic activity on wistar male rats. 
6.Lee HW and co-workers
37 
has reported the synthesis and antidiabetic activity of novel 
substituted pyrimidines having thiazolidinedione moiety were reported. These compounds were 
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evaluated for their glucose and lipid lowering activity in mice. The results exhibited considerably 
more potent biological activity than that of the reference compounds, pioglitazone and 
rosiglitazone, respectively. 
7. Mourao RH and co-workers
38
 were synthesized and evaluated thiazolidinediones for their 
glucose lowering capability and their effects on the triglyceride level in alloxan diabetic mice. 
8.Bashir A.Bhat and coworkers
39
 has reported synthesis of thiazolidinedione with carboxylic 
ester substituent’s having good antihyperglycemic activity. 
9. Sohda, T and co-workers
40
 in the year 1992 has reported the synthesis of various 5-[4-(2-or 4-
azolylalkoxy) benzyl-or-benzylidene]-2, 4-thiazolidinediones (3A and 3B) andevaluated them 
for hypoglycemic and hypolipidemic activities in insulin-resistant, genetically obese, and 
diabeticKKAymice. It has been reported that replacement of the 2-pyridyl moiety of pioglitazone 
by a 2-or 4-oxazolyl or2-or 4-thiazolyl moiety greatly enhances in vivo potency. Among the 
synthesized compounds [3A] or 5-[4-[2-(5-methyl-2-phenyl-4-oxazolyl) ethoxy] benzyl]-2, 4-
thiazolidinedione (R1= Ph, R2= Me, X= O and Y= CH2)exhibited the most potent activity which 
was about 100 times more than that of pioglitazone 
10.A series of 2, 4-thiazolidinedione-3- and 5-acetic acid amides (15A & 15B) were synthesized 
by Lesyket al
41
(2013). All the compounds were screened in vitro for anticancer activity. Among 
them 2-[5-(4-chlorobenzylidene)-2,4-dioxo-imidazolidin-3-yl]-N-(2-trifluoromethyl-
phenyl)acetamide with (Ar=4-Cl-C6H4 and R= 2-CF3-C6H4) (1)were found to be superior for 
treating leukemia.  
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(1)       (2) 
11.Tokumitsuet al 
42
(2002) worked on troglitazone, one of thiazolidinedione derivative and 
evaluated its activity in suppression of cell growth.(2)Troglitazoneshowed this activity by 
decrease in cyclin E and the hyperphosphorylated form of retinoblastoma tumor suppressor gene 
product. Troglitazone also cause a decrease in histamine secretion due to the reduced expression 
of histidine decarboxylase mRNA. 
12.Nakashiroet al 
43(2003) reported PPARγ (Peroxisome proliferator-activated receptor γ) as a 
member of the nuclearreceptor superfamily of ligand-activated transcription factors. The findings 
showed that PPARγ is expressed inhuman salivary gland tumors and its ligands inhibit the 
growth of cultured salivary gland cancer cells. Theantitumor effect of PPARγ was also expressed 
in human oral squamous cell carcinoma and it was found thatPPARγ function is inactivated in 
Oesophageal Squamous Carcinoma Cell (OSCC).  
13.Kim et al 
44
(2007) worked ontroglitazone and tested its underlying mechanism in MC3T3-E1 
cells, an established osteoblast cell line.Troglitazone increase the reactive oxygen species but 
induced cell death was not affected by the antioxidant Nacetylcysteine. 
 
14. Fischer & co-workers
45
(2006) reported that troglitazone induces cyclooxygenase-2 (COX-2) 
expression at both theprotein and mRNA level and increased production of rostaglandin E2 
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(PGE2) in cultured keratinocytes. Theinduction of COX-2 by troglitazone was almost completely 
inhibited by specific inhibitor of ERK activation. 
15. Smith et al 
46(2009) worked on PPARγ and tested for attenuation proliferation and modulate 
Wnt/β catenin signaling inmelanoma cells. Ablation of PPARγ expression in the MM96L 
melanoma cell line by siRNA mediated mechanismattenuates the anti-proliferative effect of 
these agents suggesting this effect is directly mediated by PPARγ. 
16. In vitro and in vivo anti-inflammatory effects of thiazolidinediones,(3,4) troglitazoneand 
rosiglitazone  werereported by Dandonaet al
47
(2003). It results in suppression of ROS generation 
by mononuclear cells and suppression ofp47phox, an essential protein component of 
nicotinamide adenine dinucleotide phosphate oxidase, which convertsmolecular oxygen to the 
superoxide radical. TZDs also reduce lipid peroxidation.  
 
(3)        (4) 
17. Dundar, O.Band co-workers ( 2007)
48
 reportedsome new thiazolyl  thiazolidine-2,4-dione 
derivatives (5) were synthesized and evaluated for antibacterial andantifungal activities against 
Staphylococcus aureus(ATCC25923), Methicillin resistant S. aureus (MRSA ATCC 43300), 
Methicillin resistant S.aureus (MRSA isolate) and Escherichia coli (ATCC 23556) and C. 
albicans(ATCC10145). All the compounds were found to be active against these strains.  
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(5) 
18. Gouveiaet al
49
(2011) have worked on 5-arylidene-4-thioxo-thiazolidine-2-ones(6). These 
compounds are found to be active against representative strains, including multidrug- resistant 
strains of clinical isolates. The compounds containing the 5- arylidene subunit presented greater 
antimicrobial activities against gram positive bacteria, including the multidrug- resistant clinical 
isolates, than the 4-thioxo- thiazolidine-2-one. 
 
(6) 
19. Heerding andco-workers
50 
(2003) carried out the synthesis of novel 
benzylidenethiazolidinedione (7) and found the effect of varying the secondary hydroxyl group 
on antibacterial ctivity. Compound with X = CH (OH) showed antibacterial activity against 
Gram-positive strains only. No activity was seen against Hemophilus influenza or Escherichia 
coli. Authors found that Compound with X = CH2, C (O) are inactive whereas if X = CH (NH2) 
retains Gram-positive antibacterial activity.  
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(7) 
20. Mulwad and co-worker
51
(2009) worked on thiazolidine-2,4-diones and synthesized 3-(2-oxo-
2H-benzopyran-6-yl)-thiazolidine-2,4-dione derivative(8) by the condensation of 
iminothiazolidinone with different substituted aromatic aldehydes occurred at reactive methylene 
group present at C-5 position of thiazolidin-4-one ring and resulted in the formation of 5-
arylidene-2-imino-3-(2-oxo-2H-benzopyran-6-yl)-thiazolidin-4-one. On the hydrolysis of this 
condensation product with 2% HCL to gave 3-(2-oxo-2H-benzopyran-6-yl)-thiazolidine-2, 4- 
dione. The synthesized compound screened for their antimicrobial activity against Bacillus 
subtilis, Escherichia coli and antifungal activity against Candida albicans, Aspergillusniger and 
found to exhibit significantantibacterial activities.  
 
(8) 
21. Maccari& co-workers
52
 (2002)  reported various other derivatives 5-arylidene-2, 4-
thiazolidinediones(9) were studied for their aldose reductase inhibitory  activity and among 
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these, N-unsubstitutedderivatives exerted the same inhibitory activity of Sorbinil. Introduction of 
an acetic acid chain on N-3 of the thiazolidinedione moiety led to a marked increase in inhibitory 
activity (R= 3-OC6H5). The substitution pattern on the 5-benzylidene moiety markedly 
influenced the activity of N-unsubstituted2, 4-thiazolidinediones. The findings obtained showed 
that the compounds with substituents at the metaposition being generally more effective than the 
para-substituted ones.  
 
(9) 
22. Some new derivatives of 2, 4-thiazolidinediones were prepared by Maccariet al
53
 in the year 
2006. All the compounds were tested in vitro as aldose reductase inhibitors. Compounds with N-
unsustituted5-benzyl-2, 4-thiazolidinediones and (5-benzyl-2, 4-dioxothiazolidin-3yl) acetic 
acids (R= CH2COOH and R1=3-OC6H5, 4-OC6H5, 4-C6H5, 4-OCH3)(10)gave high inhibitory 
levels.  
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(10) 
23. Pitta IR and co-workers
54
 in the year 2005 reported the acridinylidene and benzylidene 
thiazolidinedione derivatives are very much active for glucose lowering capability and also their 
effect on the triglyceride level in alloxan diabetic mice16. Compound 5-(2,4-Dimethoxy-
benzylidene)-3-(4-methyl-benzyl)-thiazolidine-2,4-dione (11,12) showed better activity due to 
thepresence of the two methoxy groups in position 2 and 4 of the benzylidene ring.  
 
(11)       (12) 
24. Synthesis of some derivatives of thiazolidine- 2, 4-diones having carboxylic ester(13) 
appendage at N-3 has been reported by Bhat B A and co-workers
55
 in the year 2004to have 
antihyperglycemic activity. The ethyl ester of thiazolidine- 2, 4-dione- 3- acetic acid showed 
higher antihyperglycemic activity than the corresponding ester because the ethyl group is 
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replaced by methylgroup. Many of these derivatives along with their corresponding carboxylic 
acids showed significant improvement on post-prandial hyperglycemia in normal rats whereas 
compound with -CF3 group showed marginal hypoglycemic activity. 
 
(13) 
25. Madhavan GR etal
56
 in the year 2002 reported that synthesis of thaizolidinediones(14) having 
pyrimidinone moiety remarkably shows activity in insulin resistant, hyperglycemic and ob/ob 
mice18. PPARγ transactivation assay was performed in Human Embroynic Kidney 293T [HEK] 
cells. PMT 13 or 5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-
pyrimidinyl]ethoxy]phenylmethyl] thiazolidine-2, 4-dione) showed the best biological activity in 
this series. 
 
(14) 
26. Lohray B B and co-workers
57
 in the year 1997 reported various thaizolidinediones(15) were 
synthesized having indole as heterocyclic moiety has been reported to have euglycemic activity. 
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Compound indicated superior euglycemic and hypolipidemic activity than Troglitazone having 
(R= H, X= CH).  
 
(15) 
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3. RESEARCH ENVISAGED 
Despite the optimal use of available anti-cancer drugs (ACDs), many patients with 
neoplasmic conditions fail to experience cell proliferation control and others do so only at the 
expense of significant toxic side effects. The limitations with the conventional ACDs highlighted 
the need for developing newer agents to treat cancer and therefore new, less toxic and more 
effective drugs are required. 
Thiazolidinediones are five member heterocyclic ring system containing sulphur and 
nitrogen atom and received much attention of medicinal chemists due to their potential biological 
activities. Various substituents at C-3 and C-5 of thiazolidinedione results in potent anti-cancer 
activity. Prompted by these reports, we aimed to prepare the following series of 5-substituted-
thiazolidinedione derivatives as potent anti-cancer agents. 
Hence the specific aims &objectives of the present study are, 
 To synthesize a series of novel 5-substituted-thiazolidinediones. 
 To characterize the synthesized compounds by IR, NMR, Mass spectra and elemental 
analysis. 
 To evaluate the test compounds for in-vitro anti-cancer activity. 
The title compounds are planned to synthesize by using the following synthetic route 
mentioned in the following scheme.   
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Step-I:
COOH
CH2Cl
+ NH2CNH2
O
S NH
O
O
Step -II
S NH
O
O
+ OHC R
S
N
H
OO
R
SCHEME
Synthesis of 2,4-Thiazolidindione
: Synthesis of 5-substitutedbenzylidene-2,4-Thiazolidindione
TZD 1-7Where R is
N(CH3)21. 2. N(CH3)2HC=HC
3. OCH3 4.
HO
5.
TZD1 TZD2
TZD3
TZD4
NO2 6.
7.
Cl
NH2
TZD5 TZD6
TZD7  
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4. EXPERIMENTAL 
4.1. Chemistry 
Melting points (mp) were determined in open capillary tubes on Thomas Hoover melting 
point apparatus and are uncorrected. The IR spectra were recorded in film or in potassium 
bromide disks using a Jasco FT-IR 410 spectrometer. The 
1
H-NMR spectra were recorded on 
DPX-300 MHz Bruker FT-NMR spectrometer. The chemical shifts were reported in parts per 
million (δ ppm) relative to TMS as an internal reference. Mass spectra were recorded on a JEOL-
SX-102 instrument using fast atom bombardment (FAB positive). Elemental analysis (C, H and 
N) was performed on a Perkin-Elmer 2400 analyzer and values were within the acceptable limits 
of the calculated values. The progress of all the reactions were monitored by readymade silica 
gel plates (Merck). Iodine and UV lamp were used as a developing agent. Spectral data (IR, 
NMR, and mass spectra) were confirmed the structures of the synthesized compounds and the 
purity of these compounds were ascertained by microanalysis. Elemental (C, H and N) analysis 
indicated that the calculated and observed values were within the acceptable limits. All 
chemicals and reagents were procured from E.Merck India Ltd., CDH, and SD Fine Chem and 
were used without further purification. 
The chemical studies of the present work are discussed under the following heads: 
Synthesis of 5-(4-Substituted) benzylidene) thiazolidine-2, 4-diones. 
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4.1.1. General procedure for synthesis of 2, 4-Thiazolidinedione 
In a 250 ml three necked flask, to a solution of chloroacetic acid (0.02 mol) in 30 ml of water 
was added a solution of thiourea (0.02 mol) dissolved in 60 ml of water. The mixture was stirred 
for 15 min to form a white precipitate, accompanied by considerable cooling. To the content of 
the flask was then added slowly 20 ml concentrated HCl drop wise, the flask was then connected 
with a reflux condenser and gentle heat applied to effect complete solution, after which the 
reaction mixture was stirred and refluxed 8 hr at 100-110ºC. On cooling the contents of the flask 
solidified to a cluster of white needles. The product was filtered and washed with cold water to 
remove traces of hydrochloric acid and dried. It was purified by recrystallization from ethyl 
alcohol. 
4.1.2. General procedure for synthesis of 5-(4-substituted) benzylidene) thiazolidine -2, 4-
diones (TZD 1-7) 
In a 250 ml three necked flask, a substituted benzaldehydes (p-dimethyl amino benzaldehyde 
(0.02mol), p-dimethylamino cinnamaldehyde (0.02mol), 4-methoxy benzaldehyde (0.02mol), 2-
hydroxy benzaldehyde (0.02mol), p-nitro benzaldehyde (0.02 mol), p-amino benzaldehydes and 
p-chloro benzaldehydes were separately suspended in toluene. To this a catalytic amount of 
piperidine (1ml) was added. The mixture was stirred and refluxed. After the complete removal of 
water and when the temperature reached above 110ºC the reaction mixture was stirred for further 
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5 hr. The content of the flask was cooled, and the product precipitated out was filtered and 
washed with water. The recrystallization was done by from ethyl alcohol.   
4.2.1. Synthesis of 2, 4-Thiazolidinedione 
Yield                             : 2.91 g; 92.0 %  
Melting Point               : 121-124 °C 
Rf Value                       : 0.72 (benzene: ethyl acetate (8:2) 
Molecular Formula      : C3H3NO2S 
Molecular Weight         : 117.13(M+) 
IR (KBr) cm
-1                       
: 3329 (NH), 3066 (Ar-CH), 1716 (C=O,Str), 688 (C-S-C).                                           
1
H NMR (CDCl3) δ ppm :
1
H NMR (CDCl3) δ (ppm): 3.76 (s, 2H,CH2),10.0(s,1H,NH). 
Elemental Analysis 
Calculated                     : C, 30.72; H, 2.57; N, 11.94. 
Found                            : C, 30.76; H, 2.58, N, 11.96.     
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4.2.2. Synthesis of 5-(4-(dimethylamino) benzylidene) thiazolidine-2, 4-dione (TZD 1) 
Yield                             : 2.86 g; 91.0 %  
Melting Point                : 156-159 °C 
Rf Value                       : 0.85 (benzene: ethyl acetate (8:2) 
Molecular Formula       : C12H12N2O2S 
Molecular Weight         : 248.06(M+) 
IR (KBr) cm
-1  
: 3310 (NH), 3085 (Ar-CH), 2948 (N(CH3)2,1696 (C=O, Str), 688 (C-S-C).                                           
1
H NMR (CDCl3) δ ppm :
1
H NMR (CDCl3) δ (ppm): 2.85 (s, 6H, CH3), 4.89(s,  
2H, NH2), 6.54 (d, J = 8.0 Hz, 2H, Ar-H), 7.12 (d, J = 8.0Hz, 2H, 
Ar-H), 7.15(s, 1H, CH), 10.0(s,1H,NH). 
Elemental Analysis 
Calculated                     : C, 58.03; H, 4.87; N, 11.25. 
Found                            : C, 58.05; H, 4.87, N, 11.28.     
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4.2.3. Synthesis of 5-(4-(dimethylamino) cinnamoylidene) thiazolidine-2,4-dione (TZD 2). 
Yield                              : 2.47 g; 82.3 %  
Melting Point                 : 194-197 °C 
Rf Value                         : 0.78 (benzene: ethyl acetate (8:2) 
Molecular Formula         : C14H14N2O2S 
Molecular Weight          : 274.08(M+) 
IR (KBr) cm
-1  
: 3396 (NH), 3085 (Ar-CH), 2948 (N(CH3)2,1712 (C=O, Str),688 (C-S-C).                                           
1
H NMR (CDCl3) δ ppm:
1
H NMR (CDCl3) δ (ppm): 2.85 (s, 6H, CH3), 6.65(s,1H, CH),6.85(s,   
1H, CH) 6.44 (d, J = 8.0 Hz, 2H, Ar-H), 7.12 (d, J =8.0Hz, 2H, 
Ar-H), 7.01(s, 1H, CH), 10.2(s,1H,NH). 
Elemental Analysis 
Calculated                      : C, 61.29; H, 5.14; N, 10.21. 
Found    : C, 61.32; H, 5.12; N, 10.24. 
 
 
 
 
 
 
SYNTHESIS AND IN-VITRO ANTICANCER EVALUATION OF NOVEL-5 SUBSTITUTED THIAZOLIDINEDIONES 
 
J.K.K.Nataraja college of Pharmacy PAGE 32 
 
4.2.4. Synthesis of 5-(4-methoxybenzylidene)thiazolidine-2,4-dione (TZD 3) 
Yield             : 2.32 g; 75.8 %   
Melting Point                 : 142-145 °C 
Rf Value                         : 0.71 (benzene: ethyl acetate (8:2) 
Molecular Formula       : C11H9NO3S 
Molecular Weight         : 235.26 (M+) 
IR (KBr) cm
-1    
: 3348 (NH), 3085 (Ar-CH), 2910 (OCH3),1674 (C=O, Str), 686 (C-S-C).                                           
1
H NMR (CDCl3) δ ppm :
1
H NMR (CDCl3) δ (ppm): 3.73 (s, 3H, CH3),6.72 (d, J =  
            8.0 Hz, 2H, Ar-H), 7.19 (d, J = 8.0Hz, 2H, Ar-H), 7.15(s,  
            1H, CH), 10.1(s,1H,NH). 
Elemental Analysis 
Calculated                      : C, 56.14; H, 3.86; N, 5.94 
Found                            : C, 56.16; H, 3.86, N, 5.95 
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4.2.5. Synthesis of 5-(2-hydroxybenzylidene)thiazolidine-2,4-dione (TZD 4)  
Yield                             : 2.65 g; 88.2 %  
Melting Point                : 181-184 °C 
Rf Value                       : 0.81 (benzene:ethyl acetate(8:2) 
Molecular Formula       : C10H7NO3S 
Molecular Weight         : 221.23(M+) 
IR (KBr) cm
-1                       
: 3532 (OH), 3308 (NH), 3085 (Ar-CH), 1702(C=O, Str), 680 (C-
S-C).                                           
1
H NMR (CDCl3) δ ppm :
1
H NMR (CDCl3) δ (ppm): 5.02(s, 1H, OH), 6.77-7.13(m, J  
   = 8.0 Hz, 4H, Ar-H), 7.42(s, 1H, CH), 10.3(s,1H,NH). 
Elemental Analysis 
Calculated                     : C, 54.29; H, 3.19; N, 6.33 
Found                            : C, 54.27; H, 3.19, N, 6.31. 
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4.2.6. Synthesis of 5-(2-(4-nitrophenyl)ethylidene)thiazolidine-2,4-dione(TZD5) 
Yield                             : 1.85 g; 82.6 %  
Melting Point                : 124-128 °C 
Rf Value                        : 0.72 (benzene:ethyl acetate(8:2) 
Molecular Formula       : C10H6N2O4S 
Molecular Weight         : 250.23(M+) 
IR (KBr) cm
-1                       
: 3348 (NH), 3085 (Ar-CH), 1674 (C=O, Str), 688 (C-S-C),1289 ( 
    NO2)                                          
1
H NMR (CDCl3) δ ppm :
1
H NMR (CDCl3) δ (ppm): 7.29 (s, J = 8.0 Hz, 1H, CH), 7.56(d, J 
=8.0  
     Hz, 4H, Ar-H), 8.14(d, J =8.0 Hz, 4H, Ar-H),10.1(s,1H,NH). 
Elemental Analysis  
Calculated                     : C, 48.00; H, 2.42; N, 11.20.   
Found                            : C, 47.98; H, 2.42, N, 11.23.  
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4.2.7. Synthesis of 5-(2-(4-aminophenyl)ethylidene)thiazolidine-2,4-dione(TZD6) 
Yield                             : 2.15 g; 86.7 %  
Melting Point                : 147-149 °C 
Rf Value                       : 0.79 (benzene: ethyl acetate (8:2) 
Molecular Formula       : C10H8N2O2S 
Molecular Weight         : 220.25(M+) 
IR (KBr) cm
 
                   : 3343 (NH),3291 (NH2), 3058 (Ar-CH), 1698 (C=O, Str), 688 (C-S-C).                                           
1
H NMR (CDCl3) δ ppm:
1
H NMR (CDCl3) δ (ppm): 4.0(s,2H,NH2),  6.41(d, J = 8.0 Hz, 4H,  
    Ar-H),7.05(d, J = 8.0 Hz, 4H, Ar-H),7.15(s,1H,CH),10.1(s,1H,NH) 
Elemental Analysis 
Calculated                     : C, 54.50; H, 3.66; N, 12.70.   
Found                            : C, 54.53; H, 3.66, N, 12.72.  
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4.2.8. Synthesis of 5-(4-chlorobenzylidene)thiazolidine-2,4-dione(TZD7) 
Yield                            : 1.96 g; 80.2 %  
Melting Point               : 172-174 °C 
Rf Value                      : 0.83 (benzene: ethyl acetate (8:2) 
Molecular Formula      : C10H6 ClNO2S   
Molecular Weight        : 239.95.02(M+), 241.06 (M+2) 
IR (KBr) cm
-1                      
: 3388 (NH), 3085 (Ar-CH), 1696 (C=O, Str), 743 ( C-Cl),688 (C-S-C).                                           
1
H NMR (CDCl3) δ ppm:
1
H NMR (CDCl3) δ (ppm): 7.15(s,1H, CH, Ar-H), 7.22 (d, J = 8.0 Hz,  
       4H,Ar-H), 7.24(d, J = 8.0 Hz, 4H, Ar-H),10.1(s,1H,NH).   
Elemental Analysis 
Calculated                    : C, 50.50; H, 2.52; N, 5.84, Cl, 14.79   
Found                           : C, 49.51; H, 2.52, N, 5.83, Cl, 14.79  
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4.3. CHROMATOGRAPHY STUDIES OF SYNTHESIZED COMPOUNDS 
 
4.3.1 THIN LAYER CHROMATOGRAPHY 
 
Thin Layer Chromatography or TLC is a solid-liquid form of chromatography here the 
stationary phase is a polar adsorbent and the mobile phase can be a single solvent or 
Combination of solvents. TLC is inexpensive technique and quick that can be used for 
determine the number of components in a mixture, verify a substance’s identity, monitor the 
process of a reaction, determine appropriate condition for column chromatography, analyze the 
fractions obtained from column chromatography. 
 
4.3.1.1 MATERIALS AND METHODS 
 
1. Preparation of plates 
 
Silica gel G was mixed in a glass mortar to smooth consistency with the requisite 
amount of water and slurry was quickly transferred to the spreader. The mixtures have been 
spread over the plates in thickness of 0.2 mm and allow setting into a suitable holder and 
after 30 minutes, plates were dried at 120
o
C, for further activation of the absorbent. 
 
2. Sample application 
 
About 2 mm of absorbent from the edge of plate was removed to give sharply defined 
edges. 2-5 µ l volumes of synthesized compounds were spotted with the help of capillary tubes, 
just above 1 cm of the bottom of coated plates. 
 
3. Development chamber 
 
 
  The chromatographic chamber was lined with filter paper dipping into mobile phase  so  
as  to  maintain  the  atmospheric  saturation  with  solvent  vapors  in  the chamber. The solvent 
front was allowed to rise to distance of about 12cm from the base line on the plate was 
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removed from the tank and allowed to dry in the air. 
 4. Solvent system 
           The choice of best developing solvent is one of the most important decisions in practical 
TLC by review of literature survey on by knowing nature of compounds, this solvent system 
used is benzene: ethyl acetate (8:2). 
 
5. Detection of components 
 
            The spots were visualized under Iodine chamber. 
 
4.3.2 COLUMN CHROMATOGRAPHY 
 
          Purification of synthesized derivatives was done by column chromatography. 
Materials 
 
    1.   Glass column of size 45 cm x 3cm. 
 
    2.   Silica gel for column chromatography 60-120 mesh size. 
 
    3.   Eluting solvent system benzene: ethyl acetate (8:2).  
 
 
Preparation of column 
 
                 The silica gel 60-120 mesh size was made into slurry with the above solvent system. 
The bottom of the column was plugged with little glass wool. Then the slurry was poured into 
the column, which is filled with solvent after two third of the column areas were filled with 
slurry. It was set aside for 30 minutes and eluting solvent was passed through column for 
several times ensure good packing of the column. After the adsorbents are settled, a filter paper 
was kept to prevent disturbance of the top layer of the adsorbent as fresh mobile phase to be 
added to column for the process of elution. The fractions were collected for every 5 ml and 
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analyzed for the presence of different of similar compound by running TLC and then allow 
evaporating to get the residue.  
4.4. Pharmacology 
         All the synthesized compounds were evaluated for their anti-cancer activity. 
4.4.1. Anti-cancer activity 
4.4.1.1. IN-VITRO ANTI-CANCER ACTIVITY 
          Tissue culture has been used  to screen may anti cancer drugs since  there  is clear 
correlation  between  the in  vitro and in  vivo activities  of  potential  chemotherapeutic agents.  
There  is  scientific  justification  for  cytotoxicity  testing  in  tissue,  since  animal models are  
in many ways  in adequate for predicting  the effects of chemicals on humans since there are 
many metabolic differences between species. 
          Cytotoxicity studies involve the analysis of morphological damage or inhibition of zone of 
outgrowth induced by the chemicals tested. 
ASSAY FOR PROLIFERATION STUDIES 
IN VITRO ANTI CANCER ACTIVITY 
          The human cervical cancer cell line (HeLa) was obtained from national center for cell 
science (NCCS), pune. The HeLa  cells were grown  in Eagles Minimum Essential Medium  
containing  10%  fetal  bovine  serum  (FBS)  and maintained  at  37°C,  5% CO2, 95% air and 
100%  relative humidity. Maintenance cultures were passaged weekly, and the culture medium 
was changed twice a week. 
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        Toxicity  of  test  compound  in  cells  was  determined  by  MTT  assay  based  on 
mitochondrial  reduction  of  yellow  MTT tetrazolium  dye  to  a  highly  colored  blue formazan 
product
40
. 
Assay for Proliferation Studies - MTT Assay 
Principle  
MTT [(3-(4,5-dimethyl thiazol-2yl)-2,5diphenyl tetrazolium bromide] measures the 
metabolic activity of the viable cells. The assay can be performed entirely in a microtiter plate 
(MTP). It is suitable for measuring cell proliferation, Cell viability or Cytotoxicity. The reaction 
between MTT and mitochondrial dehydrogenase produces water-insoluble formazan salt. This 
method involves culturing the cells in a 96 well microtiter plate and then incubating with MTT 
solution for approximately 2 hours. During incubation period, viable cells convert MTT to a 
water insoluble formazan dye. The formazan dye in the MTP is solubilized and quantified with 
an ELISA plate reader. The absorbance directly correlates with the cell number. This is 
applicable for adherent cells cultured in MTP. 
Materials for MTT assay 
 The human cervical cancer cell line (HeLa)  
 Eagles Minimum Essential Medium containing 10% fetal bovine serum (FBS) 
 Phosphate buffered saline (PBS) 
 Dimethyl sulphoxide (DMSO) 
 MTT [(3-(4,5-dimethylthiazol-2yl)-2,5 diphenyltetrazoliumbromide] 
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 CO2 incubator (WTC Binder, Germany) 
 Laminar air flow cabin (Klenzaids, Chennai, India ) 
 Refrigerated centrifuge ( Biofuge fresco, Heraeus, Germany ) 
 ELISA-reader ( For MTP ) Anthos 2010, Germany ) 
 Deep freezer (Polar Angelantioni Industries, Italy ) 
 Ultrazonic bath ( Transonic [ 460/H ], by Elma, Germany ] 
 Vaccum pump ( Zenith [model: PDF-2-2.5], Mumbai, India ) 
 Pipettes (Eppendoff, Hamburg, Germany ) 
 Culture plates 
 Centrifuge tubes 
 Aerosol resistant tips 
 Flat-bottomed 96-MTP 
 Tissue culture grade 
Cell treatment procedure 
          Cell treatment procedure The monolayer  cells were detached with  trypsin-
ethylenediaminetetraacetic  acid (EDTA)  to  make  single  cell  suspensions  and  viable  cells  
were  counted  using  a hemocytometer  and  diluted with medium with  5%  FBS  to  give  final  
density  of  1x105 cells/ml.  one  hundred microlitres  per well  of  cell  suspension were  seeded  
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into  96-well plates at plating density of 10,000 cells/well and incubated to allow for cell 
attachment at 370 C, 5% CO2, 95%  air  and 100%  relative humidity.  
        After 24 h the cells were treated with serial concentrations of the extracts and fractions. 
They were  initially dissolved  in neat  dimethylsulfoxide  (DMSO)  and  further  diluted  in  
serum  free medium  to  produce five concentrations. One hundred microlitres per well of each 
concentration was added to plates to obtain final concentrations of 100, 10, 1.0 and 0.1 µM. The 
final volume in each well was  200  µl  and  the  plates were  incubated at  370 C, 5% CO2,  95%  
air  and  100% relative  humidity for  48h.  The medium containing without  samples  were  
served  as control. Triplicate was maintained for all concentrations.   
Procedure 
In-vitro anticancer screening 
The human cervical cancer cell line (HeLa) was obtained from National Centre for Cell 
Science (NCCS), Pune. The cells were grown in Eagles Minimum Essential Medium containing 
10% fetal bovine serum (FBS). 
For screening experiment, the cells were seeded into 96-well plates in 100µl of medium 
containing 5 %  FBS, at plating density of 10,000 cells/well and incubated at 37 
0
C, 5 % CO2, 95 
% air and 100 % relative humidity for 24 hours prior to addition of samples. The samples were 
solubilized in Dimethyl sulfoxide and diluted in serum free medium. After 24 hours, 100 µl of 
the medium containing the samples at various concentration ( eg; 0.063, 0.125, 0.25, 0.5, 1.0 mM 
etc… ) was added and incubated at 370C, 5% CO2, 95% air and 100% relative humidity for 48 
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hours. Triplicate was maintained and the medium containing without samples were served as 
control
41
. 
After 48 hours, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) was added to 
each well and incubated at 37 
0
C for 4 hours. The medium with MTT was then flicked off and 
the formed formazan crystals were solubilized in 100µl of DMSO and then measured the 
absorbance at 570 nm using micro plate reader. The % cell inhibition was determined using the 
following formula.  
                       % cell Inhibition = 100 – {(sample) / Abs (control)} × 100 
Nonlinear  regression  graph  was  plotted  between  %  Cell  inhibition  and  Log10 
concentration and IC50 was determined using GraphPad Prism software.   
4.4.1.2. Statistical Analysis 
All values are expressed as mean ± SEM. Data were analyzed by non-parametric ANOVA 
followed by Dunnett’s multiple comparison tests, and other data was evaluated using GraphPad 
PRISM software. A p-value < 0.05 was considered significantly different. 
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5. RESULTS AND DISCUSSION 
5.1. Chemical work: 
The results of the present work are discussed under the following heads. 
Scheme: Synthesis of 5-(4-substituted) benzylidene) thiazolidinediones (TZD 1-7). 
5.1.1.Synthesis of 5-(4-substituted)benzylidene) thiazolidine-2, 4-diones 
Synthetic route depicted in scheme outline the chemistry part of the present work. The 
4-(4-substituted) benzylidene) thiazolidine-2,4-diones(TZD1-7)were obtained by the 
condensation of thiazolidine-2,4-diones with substituted aldehydesin presence of toluene and 
piperidine. The formations of the thiazolidine-2, 4-diones were confirmed by the presence of 
characteristic peaks in the IR spectra. It showed characteristic peak around 3380 cm
-1 
for NH 
stretching, peaks around 3085 cm
-1
 for CH3 stretching, peak around 1700 cm
-1 
due to the 
presence of  C=O stretching and peak at around 688 cm
-1
for C-S-C groups. The NMR spectra 
of the compounds TZD 1-7showed the characteristic peak at around δ 2.80 ppm for CH3 
group, δ 3.00 ppm for CH2 and δ 10.00 ppm for NH and also shows multiplet in the range of 
δ 6.70-7.54 ppm owing to aromatic protons. The appearance of peak due to chlorine, bromine 
and fluorine in IR spectra around 700 -800 cm
-1 
and formation M+2 peak in the mass spectra.  
Data from the elemental analyses and molecular ion recorded in the mass spectra further 
confirmed the assigned structure.  
5.2. Pharmacological Investigation 
The anticancer screening of title compounds (TZD1-7) were evaluated against human 
cervical cancer cell line (HeLa) by MTT assay method. In  this assay  the effective  ranges of 
anticancer  activity  for compounds TZD1-7 were in the concentration of 0.1, 1.0, 10, 100 µM 
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respectively in the  human  cervical  cancer  cell line (HeLa). Triplicate was maintained and 
the medium containing without samples were served as control. 
  TZD1 (p- dimethylamino group) produced IC50 value 45.70 µM in case of the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample has more 
anticancer activity. The compound TZD1 (p- dimethylamino group) had shown the  
percentage  of  cell inhibition was 74.85 against the human  cervical  cancer  cell  line (HeLa) 
in  the highest concentration, which have p- dimethylamino group in the thiazolidinone 
nucleus.     
The result indicates that TZD1 (p-dimethylamino group) showed a significant anticancer 
activity against the human cervical cancer cell line (HeLa), when compared to that control.  
 TZD2 (dimethylamino cinnamoyl group) produced IC50 value 66.23 µM in case of 
the human cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compound TZD2 (dimethylamino cinnamoyl group) had  
shown  the  percentage  of  cell inhibition  was 52.89 against  the  human  cervical  cancer  
cell  line  (HeLa) in  the highest concentration, which have dimethylamino cinnamoyl group 
in the thiazolidinone nucleus.    
  The results indicate that TZD2 (dimethylamino cinnamoyl group) showed a moderate 
anticancer activity against the human cervical cancer cell line (HeLa), when compared to that 
of control.  
  TZD3 (4-methoxyl group) produced IC50 value 75.26µM in case of the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample has more 
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anticancer activity. The compound TZD2 (4-methoxyl group) had shown the percentage of 
cell inhibition was 52.25 against the human cervical cancer cell line (HeLa), which have 
dimethylamino group in the thiazolidindione nucleus.    
The results indicate that TZD3 (4-methoxyl group) showed a less anticancer activity against 
the human cervical cancer cell line (HeLa), when compared to control. 
 TZD4 (2-hydroxyl group) produced IC50 value 92.36 µM in case of the human cervical 
cancer cell line (HeLa). Relatively less value of IC50 indicates the sample has more 
anticancer activity. The compound TZD4 (2-hydroxyl group)had  shown  the percentage of 
cell inhibition  was 63.82against  the  human  cervical  cancer  cell  line  (HeLa) in  the 
highest  concentration, which have  imidazole group in  the  thiazolidinedione nucleus.  
 The results indicate that TZD4 (2-hydroxyl group) showed a moderate significant 
anticancer activity against the human cervical cancer cell line (HeLa), when compared to that 
of control. 
 TZD5 (p-nitro group) produced IC50 value 75.26 µM in case of the human cervical 
cancer cell line (HeLa). Relatively less value of IC50 indicates the sample has more 
anticancer activity.  The  compound TD5  (p-nitro group) had  shown  the  percentage  of  cell 
inhibition  was 55.05 against  the  human   cervical  cancer  cell  line  (HeLa) in  the highest 
concentration, which have vinyl group in the thiazolidinedione nucleus.  
The results indicate that TZD5 (p-nitro group) showed a moderate significant 
anticancer activity against the human cervical cancer cell line (HeLa), when compared to that 
of control.  
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TZD6 (p-amino phenyl group) produced IC50 value 48.60 µM in case of the human 
cervical cancer cell line (HeLa). Relatively high value of IC50 indicates the sample has more 
anticancer activity. The  compound TZD6 (p-amino phenyl group) had  shown  the  
percentage  of  cell inhibition  was 73.85 against  the  human  cervical  cancer  cell  line  
(HeLa) in  the highest concentration, which have p-amino group in the thiazolidinone 
nucleus.   
The  results  indicates  that TZD6 (p-amino phenyl group) showed  a good  significant 
anticancer activity against  the human cervical cancer cell  line  (HeLa), when compared  to  
that of control. 
TZD7 (p-chloro phenyl group) produced IC50 value > 100 µM in case of the human 
cervical cancer cell line (HeLa). Relatively high value of IC50 indicates the sample has more 
and significant anticancer activity. The  compound TD7 (p-chloro phenyl group) had  shown  
the  percentage  of  cell inhibition  was 55.05 against  the  human  cervical  cancer  cell  line  
(HeLa) in  the highest concentration, which have p-chloro group in the thiazolidinedione 
nucleus.    
The  results  indicates  that TZD7 (p-chloro phenyl group)  showed  a more significant 
anticancer activity against  the human cervical cancer cell  line  (HeLa), when compared  to  
that of control.   
The best mean IC50 values were achieved with compound (TZD3, TZD4, TZD5 and 
TZD7) with slight difference among them.  
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Title compounds (TZD1-7) were found to exhibit mild to moderate anticancer activities in 
cell lines and the results were summarized below: 
 Compound TZD1 (dimethylamino group) shows less activity against the HeLa (IC50 – 
47.50) cancer cell lines.  
 Compound TZD2 (dimethylaminocinnamoyl group) shows moderate activity against 
the HeLa (IC50 – 66.23) cancer cell lines. 
 Compound TZD3 (p-methoxyl group) shows high significant activity against the HeLa 
(IC50 72.56) cancer cell lines.    
 Compound TZD4 (2-hydroxl group) shows more & potent significant against the HeLa 
(IC50 –92.36) cancer cell lines.  
 Compound TZD5 (p-nitrophenyl group) shows the moderate activity against the HeLa 
(IC50 – 68.25) cancer cell lines.  
 Compound TZD6 (4-aminophenyl group) shows less significant activity against the 
HeLa (IC50 –48.60) cancer cell lines.     
 Compound TZD7 (p-chlorophenyl group) shows very high and potent significant 
activity against the HeLa (IC50 > 100) cancer cell lines. 
Among the test compounds, compound 5-(4-chlorobenzylidene)thiazolidine-2,4-dione 
(TZD7) was found to be the most active agent which showed 74.85 percentage  of  cell 
inhibition against  the  human  cervical  cancer  cell  line (HeLa) in  the highest concentration, 
which have p-chlorophenyl group at 5
th
 position in the thiazolidinedione nucleus.  
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TZD4  
 
0.1µM                                                         1µM 
 
10µM                                                         100µM 
 
   Normal
SYNTHESIS AND IN-VITRO ANTICANCER EVALUATION OF NOVEL-5 SUBSTITUTED THIAZOLIDINEDIONES 
 
J.K.K.Nataraja college of Pharmacy PAGE 54 
  
 
TZD5  
 
0.1µM                                                       1µM 
 
10µM                                                       100µM 
 
Normal
SYNTHESIS AND IN-VITRO ANTICANCER EVALUATION OF NOVEL-5 SUBSTITUTED THIAZOLIDINEDIONES 
 
J.K.K.Nataraja college of Pharmacy PAGE 55 
  
TZD6  
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           TableNo.3: IC50Values of SynthesizedCompounds (TZD1–TZD7) 
 
 
COMPOUND  CODE 
 
IC50 (MICRO MOLAR) 
 
TZD1 
45.70 µM 
TZD2 
66.23 µM 
TZD3 
75.26 µM 
TZD4 
92.36 µM 
TZD5 
68.25 µM 
TZD6 
48.60 µM 
TZD7 
 
             >100 µM 
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TableNo.4.TZD1 
 
 
Concentration (µM) 
 
%Growth inhibition 
 
IC50 
 
R
2 
 
0.1µM 
1.3342 
 
 
 
45.70 
 
 
 
0.9995 
 
1µM 
12.6079 
 
10µM 
33.8761 
 
100µM 
74.8578 
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TableNo.5.TZD2 
 
Concentration (µM) %Growth inhibition IC50 R
2 
 
0.1µM 
 
1.0424 
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1µM 
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TableNo.10.TZD3 
 
Concentration (µM) 
 
%Growth inhibition 
 
IC50 
 
R
2 
 
0.1µM 
3.1895 
 
 
 
75.26 
 
 
 
0.9916 
 
1µM 
14.2646 
 
10µM 
23.6772 
 
100µM 
55.0587 
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TableNo.11.TZD4 
 
Concentration (µM) 
 
%Growth inhibition 
 
IC50 
 
R
2 
 
0.1µM 
1.4315 
 
 
 
92.36 
 
 
 
0.9916 
 
1µM 
19.6317 
 
10µM 
35.4864 
 
100µM 
63.8275 
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TableNo.7. TZD5 
 
 
Concentration (µM) 
 
%Growth inhibition 
 
IC50 
 
R
2 
 
0.1µM 
1.5342 
 
 
 
68.25 
 
 
 
0.9367 
 
1µM 
12.9079 
 
10µM 
30.9861 
 
100µM 
60.8578 
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TableNo.9.TZD6 
 
 
Concentration (µM) 
 
%Growth inhibition 
 
IC50 
 
R
2 
 
0.1µM 
1.2342 
 
 
 
48.60 
 
 
 
0.9916 
 
1µM 
12.3079 
 
10µM 
32.9861 
 
100µM 
73.8578 
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      TableNo.6.TZD7 
 
 
Concentration (µM) 
 
%Growth inhibition 
 
IC50 
 
R
2 
 
0.1µM 3.4112 
 
 
 
>100 
 
 
 
0.9907 
 
1µM 13.7176 
 
10µM 33.8976 
 
100µM 
74.8578 
 
 
  
 
 
 
 
 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
0 20 40 60 80 100 120 
%
 C
el
l 
In
h
ib
it
io
n
 
Concentarion in µM 
SYNTHESIS AND IN-VITRO ANTICANCER EVALUATION OF NOVEL-5 SUBSTITUTED THIAZOLIDINEDIONES 
 
J.K.K.Nataraja college of Pharmacy PAGE 65 
 
6. SUMMARY & CONCLUSION 
In summary, a new series of 4-substituted benzylidene thiazolidinedione derivatives were 
synthesized. These title compounds containing seven different substituent’s at C-5 were screened 
for their invitro anti-cancer activity. Most of the test compounds were found to exhibit 
significant anti-cancer activity. Among the substituent’s at C-5, 4-dimethylaminocinnamoyl 
phenyl substituent showed maximum potency, while 2-hydroxy phenyl substituent showed 
equipotent activity but the4-dimethylamino) phenyl,4-methoxyphenyl and but-2-
enylidenesubstituent’s exhibited least activity when compare to other substituent’s. The order of 
activity at C-5 is4-dimethylaminocinnamoyl phenyl ≥2-hydroxy phenyl ≥4-dimethylamino) 
phenyl ≥4-methoxyphenyl ≥ but-2-enylidene group.  
Among the test compounds, compound 5-(4-chlorobenzylidene)thiazolidine-2,4-dione (TZD7) 
was found to be the most active agent which showed 74.85 percentage  of  cell inhibition against  
the  human  cervical  cancer  cell  line (HeLa) in  the highest concentration, which have p-chloro 
groupat the 5
th
 position in the thiazolidinedione nucleus.  
Hence this molecule can be selected as a lead molecule of the present study for further 
exploitation.  
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7. FUTURE PLAN OF WORK 
 
 
It may conclude that further beneficial pharmacophore modifications in the design of 
novel 5-substituted thiazolidinedione derivatives may be synthesized by designing novel 
ligands for therapeutic target by substituting different functional group and also examine 
with the help of NMR and X-ray which provide three dimensional frame & crystallographic 
works which can analyze structure activity data and can guide the design and synthesis of 
future potential therapeutic drugs towards other chronic disorders. 
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